Haematological toxicity associated with antineoplastic drugs: a pharmacovigilance analysis based on the FDA adverse event reporting system database. (PubMed, Front Immunol) - Oct 1, 2026 - "The leading drugs by report frequency were lenalidomide (ROR (Reporting Odds Ratio) = 1.51), methotrexate (ROR = 2.98), and rituximab (ROR = 3.69). Our findings reveal a strong signal of haematological toxicity associated with antitumour agents, supporting enhanced routine monitoring to mitigate clinical risks. Nevertheless, confirmation through pharmacoepidemiological studies with rigorous causality assessment is required, owing to the inherent limitations of the FAERS spontaneous reporting system."
Adverse events • Journal • Retrospective data • Hematological Disorders • Oncology • Solid Tumor
|